standard, and setting a cut-off scores of Ն20 for the DMI-18, >8 for the HADS, >5 for the PHQ-9, and >4 for the BDI-FS to diagnose depression. CONCLUSIONS: The Spanish validated DMI-18 scale maintains an adequate conceptual and semantic equivalence with the original and is easily understood by patients. It also has shown adequate sensitivity and specificity in the detection of affective disorders with similar results to those of the original version (sensitivity 91.7%-95.0%, specificity 68.1%-72.4%). Its sensitivity to detect depression is comparatively lower than the sensitivity of the convergent measures, but its specificity if notably better.
PMH45 A COMPARISON OF PATIENT AND PHYSICIAN ATTITUDES TOWARDS THE GOALS FOR THE TREATMENT OF SCHIZOPHRENIA IN GERMANY
Rudolph I 1 , Bridges JF 2 , Schmeding A 1 1 Janssen-Cilag GmbH, Neuss, Germany, 2 Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA BACKGROUND: Patient centered care requires physicians to accommodate views and needs of patients, but to date there has been little evidence as to the degree of concordance between patients and physicians in terms of their treatment goals and its achievement. OBJECTIVES: To identify, value and compare the treatment goals of patients and physicians for the treatment of schizophrenia, and to measure self reported and physician performance of patients with respect to these goals. METHODS: A mixed methods approach was taken combining qualitative and quantitative data. First, 20 relevant treatment goals were identified through patient focus groups (n = 30) and literature. A survey was then developed to rank the goals and to rate its importance using 5-point Likert scales. Finally degree of achievement was assessed. The survey was administered to both patients (n = 105) and physicians (n = 160) by trained field workers. Data was analyzed using means and t-tests as appropriate. RESULTS: We found that the three most important goals for patients were: reduction of anxiety (80.5), improvement of cognitive abilities (79.25), and reduced feelings of depression (79). Physicians rated: reduction of symptoms (82.25), increase of self-confidence (80.75), and improvement of cognitive abilities (80.5) as having the highest importance. When asked to rate the performance of patients with respect to these goals, we found that physicians continuously judged more critical than patients. Significant differences were found for improvement of cognitive abilities (p < 0.05), increase of independence (p < 0.05), decrease lack of emotion (p < 0.05), increase of overallsatisfaction (p < 0.05), improved ability to express oneself (p < 0.05), and recreation of social contacts (p < 0.05). CONCLU-SIONS: Results suggest that schizophrenic patients and physicians value treatment goals and their achievement relative discordant. As schizophrenic patients are capable to state their requirements, this should be considered in treatment decisions to improve treatment outcomes.
PMH46 PATIENT PREFERENCES IN ADHD-DISCRETE CHOICE EXPERIMENT
Mühlbacher AC 1 , Rudolph I 2 , Lincke HJ 1 , Nübling M 1 1 Gesellschaft für empirische Beratung mbH, D-79211 Denzlingen, Germany, 2 Janssen Cilag GmbH, Neuss/Germany, D-41470 Neuss, Germany OBJECTIVES: While the clinical efficacy of drugs for ADHD is widely studied in clinical trials (usually randomised controlled trials, RCTs), patient preferences with regard to their treatments are not well understood and therefore considered to a less extend. Aim of this study therefore was to explore the patients perceptions of an "ideal treatment" for ADHD. METHODS: Examination of the state of the art as reported in the literature was followed by a qualitative study with four focus groups consisting of 6-8 parents of ADHD-patients each. In a subsequent quantitative study phase, data was collected in an online or paper-pencil self-fill-in questionnaire for parents of patients and patient (age >14 years) themselves. It included sociodemographic data, treatment history and actual treatment and patients preferences of therapy characteristics using direct measurement (23 items on a 5-point Likert-scale) as well as a discrete-choiceexperiment (DCE, 8 pairs with 6 characteristics). RESULTS: N = 213 questionnaires were filled; most of them by the parents of patients (79% by the mothers, 9% by the fathers). Most of the patients were male (83%) and most of them (83%) had actual medical treatment of ADHD. Direct measurement showed "good emotional quality of live", "no addiction on medication", "improvement of concentration capability," and "few side effects" in the first places. In the DCE, alternatives with "better social quality of life (friendships etc. possible)", "better emotional quality of life (disease not all of the time mentally present)", and "longer duration of medication effect" were more likely to be chosen, giving thus similar results. CONCLUSIONS: N = 213 questionnaires were filled; most of them by the parents of patients (79% by the mothers, 9% by the fathers). Most of the patients were male (83%) and most of them (83%) had actual medical treatment of ADHD. Direct measurement showed "good emotional quality of live", "no addiction on medication", "improvement of concentration capability," and "few side effects" in the first places. In the DCE, alternatives with "better social quality of life (friendships etc. possible)", "better emotional quality of life (disease not all of the time mentally present)", and "longer duration of medication effect" were more likely to be chosen, giving thus similar results.
PMH47 QUANTIFYING UNMET NEEDS AMONG PATIENTS WITH DEPRESSION USING AN SSRI OR SNRI ACROSS FIVE EUROPEAN COUNTRIES USING PATIENT-REPORTED SURVEY DATA
Wagner S, Kannan H, Bolge SC Consumer Health Sciences, Princeton, NJ, USA OBJECTIVES: Traditionally, unmet needs are assessed using claims data, clinician-reported metrics, or patient-reported metrics from clinical trials. We seek to use patient-reported survey data from five European countries to quantify unmet needs of patients with depression currently using selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). This study will highlight the benefits of patient-reported survey data. METHODS: We analyzed data from the 2007 European National Health and Wellness Survey, an annual, cross-sectional, patient-reported survey of adults (aged 18+) in France, Germany, Italy, Spain, and the UK. The sample for analysis consisted of patients with diagnosed depression currently using an SSRI or SNRI and excluded patients with bipolar disorder. Unmet needs were defined as an affirmative response to the following symptoms in the past month: bothered by feeling down, depressed or hopeless; and bothered by having little interest or pleasure in doing things. Survey data were projected to national populations. Chi-square was used to test for differences across countries. RESULTS: We found 1630 SSRI and 355 SNRI users in the sample, projecting to 6.93 and 1.46 million, respectively. There were 82.5% of SSRI users and 84.3% of SNRI users who were bothered by feeling down, depressed, or hopeless, equating to 5.71 and 1.23 million, respectively. Simi-
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